| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 19,000 | $317.97 | $6,041,413.58 | -30.9% | +11.1% | - | |
| Mar 4, 2026 | UTHR United Therapeutics Corporation | Thompson Tommy G51 | Director | Sell | 2,000 | $489.42 | $978,839.40 | -19.1% | +11.1% | - | |
| Mar 3, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $499.42 | $4,744,466.67 | -11.5% | +11.7% | - | |
| Mar 2, 2026 | LQDA Liquidia Corporation | Boyle Dana | Chief Accounting Officer | Sell | 445 | $30.58 | $13,608.10 | -0.2% | +99.9% | - | |
| Mar 2, 2026 | LQDA Liquidia Corporation | Krepp Sarah | Chief Human Resource Officer | Sell | 276 | $30.58 | $8,440.08 | -0.2% | +99.9% | - | |
| Mar 2, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $515.37 | $4,896,019.01 | -11.5% | +8.4% | - | |
| Mar 2, 2026 | LQDA Liquidia Corporation | Kaseta Michael58 | CFO And COO | Sell | 1,165 | $30.58 | $35,625.70 | -0.3% | +99.9% | - | |
| Feb 27, 2026 | UTHR United Therapeutics Corporation | Olian Judy D.60 | Director | Sell | 200 | $509.55 | $101,910.00 | -4.0% | +11.5% | - | |
| Feb 23, 2026 | UTHR United Therapeutics Corporation | Benkowitz Michael47 | President And COO | Sell | 14,440 | $472.13 | $6,817,499.44 | -100% | +19.9% | - | |
| Feb 20, 2026 | PLNH Planet 13 Holdings Inc. | Wren Chris | VP Of Operations | Sell | 30,000 | $0.17 | $5,145.00 | -0.7% | - | - | |
| Feb 19, 2026 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 8,300 | $476.34 | $3,953,588.22 | -2.4% | +17.4% | - | |
| Feb 19, 2026 | SUPN Supernus Pharmaceuticals, Inc. | Sensenig Bethany | Director | Sell | 4,475 | $51.01 | $228,264.93 | -57.9% | -5.2% | - | |
| Feb 17, 2026 | UTHR United Therapeutics Corp | Malcolm Jan | Director | Sell | 50 | $474.68 | $23,734.00 | -18.5% | +17.9% | - | |
| Feb 17, 2026 | JNJ Johnson & Johnson | Reed John C | EVP, Innovative Medicine, R&D | Sell | 53,931 | $243.00 | $13,105,233.00 | -59.6% | -6.8% | - | |
| Feb 17, 2026 | JNJ Johnson & Johnson | Wolk Joseph J | Exec VP, CFO | Sell | 89,654 | $242.80 | $21,767,826.99 | -40.7% | -6.8% | - | |
| Feb 17, 2026 | JNJ Johnson & Johnson | Swanson James D. | EVP, CIO | Sell | 62,080 | $243.39 | $15,109,758.99 | -45.0% | -6.8% | - | |
| Feb 12, 2026 | TLPH Talphera, Inc. | Aslam Shakil | Chief Medical Officer | Buy | 35,000 | $0.81 | $28,430.50 | +72.6% | +11.0% | - | |
| Feb 12, 2026 | TLPH Talphera, Inc. | Angotti Vincent J.56 | Chief Executive Officer | Buy | 105,364 | $0.81 | $85,587.18 | +21.9% | +11.0% | - | |
| Feb 12, 2026 | KNSA Kiniksa Pharmaceuticals International, Plc | Quart Barry D64 | Director | Sell | 2,800 | $45.00 | $126,000.00 | -10.0% | +32.2% | - | |
| Feb 12, 2026 | TLPH Talphera, Inc. | Dasu Badri N | Chief Engineering Officer | Buy | 35,000 | $0.81 | $28,430.50 | +84.9% | +11.0% | - | |
| Feb 12, 2026 | TLPH Talphera, Inc. | Asadorian Raffi | Chief Financial Officer | Buy | 45,000 | $0.81 | $36,553.50 | +97.3% | +11.0% | - | |
| Feb 11, 2026 | PBH Prestige Consumer Healthcare Inc. | Zerillo Jeffrey | Senior VP Operations | Sell | 1,000 | $65.93 | $65,930.00 | -2.4% | -23.6% | - | |
| Feb 11, 2026 | PAHC Phibro Animal Health Corp | Bendheim Jack49 | President And CEO | Sell | 72,198 | $51.77 | $3,737,711.22 | -23.2% | -29.0% | - | |
| Feb 5, 2026 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 8,300 | $483.25 | $4,010,939.67 | -3.3% | +24.6% | - | |
| Feb 4, 2026 | KNSA Kiniksa Pharmaceuticals International, Plc | Quart Barry D64 | Director | Sell | 15,960 | $45.22 | $721,634.60 | -29.8% | +30.4% | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.